Even after stopping tesamorelin, people with HIV who had lost belly fat still had better liver enzyme levels for a full year, even though some fat came back.

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.